EssilorLuxottica (ESLOY) Stock Price & How to Invest

Last updated November 2026

Short answer

ESLOY is the US over-the-counter ADR of EssilorLuxottica, the Paris-based group behind Ray-Ban, Oakley, Varilux lenses, LensCrafters and Sunglass Hut, and the maker of Ray-Ban Meta AI glasses. Each ADR equals half an ordinary share and trades in dollars, near ~$96 on November 20, 2026, down ~39% year to date. The case rests on steady lens and eyewear demand, myopia management and AI glasses, priced at ~22x forward earnings.

ESLOY stock price

As of 2026-11-20, EssilorLuxottica (ESLOY) last closed at $95.06, down 46.4% over the past year. Over the past 52 weeks it has traded between $79.57 and $181.56.

ESLOY last close
$95.06
1 day
-1.81%
1 month
-2.69%
1 year
-46.45%
52-week range
$79.57 to $181.56
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or EssilorLuxottica's investor relations page. Walnut is informational, not investment advice.

ESLOY key stats

At $95.06 on November 20, 2026, EssilorLuxottica (ESLOY) has a market cap of $87.2B, a P/E of 30.5 on trailing earnings (21.4 on forward earnings) and a dividend yield of 2.44%.

Market cap
$87.2B
P/E (trailing)
30.5
P/E (forward)
21.4
EPS (trailing 12 months)
$3.12
Price to book
2.0
Dividend yield
2.44%
Beta
0.54

Market cap, P/E and yield are measured at the $95.06 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with EssilorLuxottica (ESLOY)?

The last two weeks for EssilorLuxottica, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • ESLOY closed at $95.06 on November 20, 2026, down 5.5% over the past five trading days (from $100.55).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does EssilorLuxottica (ESLOY) do?

EssilorLuxottica is the world's largest eyewear company. It was formed in 2018 when French lens maker Essilor merged with Italian frame maker Luxottica, and it now covers almost every step between an eye exam and a pair of glasses. It designs and makes prescription lenses (Varilux, Crizal, Transitions, Stellest for children's myopia), owns frame and sunglass brands such as Ray-Ban, Oakley, Persol and Oliver Peoples, makes licensed frames for Chanel, Prada and others, and runs retail chains including LensCrafters, Sunglass Hut, Target Optical in the US and Salmoiraghi & Viganò in Italy. Through its partnership with Meta it also makes Ray-Ban Meta and Oakley Meta AI glasses, and it sells Nuance Audio hearing glasses. ESLOY is a sponsored ADR on the OTC market: one ADR represents half an ordinary share listed in Paris under EL, and it trades in US dollars while the company reports in euros.

Revenue for 2025 was ~€28.5 billion, up 11.2% at constant currency, though adjusted operating margin slipped to ~15.7% as the company spent on AI glasses, R&D and medtech. 2026 has gone better on margins. First-half revenue rose 9.7% at constant currency to ~€14.8 billion and adjusted operating profit grew ~15%, for a margin of ~18.6%. Third-quarter revenue, reported on October 20, came to ~€7.49 billion, up 7.2% at constant currency and above the ~€7.36 billion analysts expected. Direct-to-consumer sales grew 10.6%, Asia-Pacific grew 15.7%, myopia management grew 24%, and wearables reached ~€486 million, up 20%, a sharp slowdown from the near doubling in the second quarter.

The stock has been volatile. The Paris shares fell from a record above €320 in late 2025 to a low near €138 in 2026 on worries about AI glasses competition from Google and Apple, slower wearables growth and thinner margins, then jumped about 14% the day after the third-quarter beat. That bounce has since faded: ESLOY closed at ~$95.79 on November 20, 2026, down 5.7% over the past month, 38.6% year to date and 46% over one year, against a 52-week range of ~$79 to ~$182. The market value is ~$88 billion. That is ~22x forward earnings and ~31x trailing earnings, with a €4.00 dividend per ordinary share (a yield of roughly 2.4% at the current ADR price). Ownership is also in the news: Delfin, the Del Vecchio family holding company and EssilorLuxottica's largest shareholder, is the subject of a family contest, with Bloomberg reporting on October 29 that an heir rejected a $3.9 billion offer for a stake and MT Newswires reporting on November 2 that Citigroup is financing Leonardo Maria Del Vecchio's push to gain control of Delfin.

What's driving EssilorLuxottica (ESLOY)?

1. AI glasses and the Meta partnership

Wearables, mainly Ray-Ban Meta and Oakley Meta glasses plus Nuance Audio, brought in ~€1.26 billion over the first nine months of 2026 and ~€486 million in the third quarter alone, now about 6.5% of quarterly revenue. Growth slowed to 20% at constant currency in the third quarter after nearly doubling in the second, and analysts at Deutsche Bank and Bernstein have pointed to a hard fourth-quarter comparison after the strong holiday 2025 season. Meta owns roughly 3% of EssilorLuxottica and supplies the software and AI, while EssilorLuxottica supplies brands, manufacturing and retail. The $799 Ray-Ban Display, with a built-in screen, is the higher-priced test of whether this line becomes a lasting category.

2. Myopia management and medtech

Stellest lenses, designed to slow the progression of short-sightedness in children, are the fastest-growing part of the lens business: the myopia portfolio grew 24% at constant currency in both the second and third quarters of 2026. Myopia is rising quickly across Asia, which helps explain why Asia-Pacific grew 15.7% in the third quarter, with double-digit gains in Greater China, India, Japan and South Korea. The company is also building a medical arm through acquisitions such as Heidelberg Engineering (diagnostic imaging) and newly consolidated eye clinics. CEO Francesco Milleri has tied a recovery in the share price to finishing this medtech shift, which carries higher margins and a more clinical, less fashion-driven customer base.

3. Retail and direct-to-consumer growth

Direct-to-consumer sales reached ~€4.09 billion in the third quarter, up 10.6% at constant currency, more than half of group revenue. Comparable-store sales grew in the high single digits, helped by Sunglass Hut, LensCrafters and Target Optical in North America and by double-digit retail growth in Italy, Spain and Turkey. Owning the store gives EssilorLuxottica the full margin on a frame and lenses sold together, and it is also the main channel for AI glasses demonstrations and fittings. E-commerce stays small at about 7% of revenue. Acquisitions such as Top Charoen in Thailand extend this model into faster-growing markets, though they add integration work and some debt.

4. Margins, cash flow and capital return

Adjusted operating margin fell to ~15.7% in 2025 and recovered to ~18.6% in the first half of 2026, as the core lens and frame business absorbed spending on AI, R&D and medical capabilities. Management's five-year outlook calls for solid revenue growth with adjusted operating profit growing broadly in line, which signals little margin expansion from here. First-half free cash flow was ~€1.07 billion. Net debt rose to ~€13.4 billion (including ~€3.9 billion of lease liabilities) from ~€10.9 billion at the end of 2025, partly from acquisitions. The €4.00 dividend carries a scrip option, and about 70% of shareholders took new shares in 2026, which kept cash out low but adds to the share count.

What are the risks to EssilorLuxottica (ESLOY)?

Wearables are the largest swing factor. Growth slowed from nearly 100% in the second quarter to 20% in the third, and analysts expect a tough fourth-quarter comparison. Google has announced Gemini-powered glasses with partners including Warby Parker and Gentle Monster, and Bloomberg has reported Apple is working toward its own glasses for 2027. If smart glasses hardware becomes a commodity, EssilorLuxottica's role as Meta's manufacturer could earn less. The company also depends on Meta for the AI and software, and Meta paused Ray-Ban Display launches outside the US over supply shortages, which led Baader to downgrade the stock. US tariffs weigh on frames made in Italy and China. The dollar matters twice: North America is ~43% of revenue, so a weak dollar trims reported euro sales, and the ADR price also moves with the euro/dollar rate. The valuation (~31x trailing earnings) leaves little room for a miss. Control of Delfin, the family holding company that is the largest shareholder, is being contested among Del Vecchio heirs, and a change in who runs it could change how the group is governed. Net debt has climbed to ~€13.4 billion on acquisitions, and the scrip dividend slowly dilutes holders. French withholding tax applies to dividends paid to US ADR holders, and OTC trading in ESLOY is thinner than in the Paris shares.

Is ESLOY a buy or a sell?

We give no verdict on EssilorLuxottica. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. AI glasses and the Meta partnership. Wearables, mainly Ray-Ban Meta and Oakley Meta glasses plus Nuance Audio, brought in ~€1.26 billion over the first nine months of 2026 and ~€486 million in the third quarter alone, now about 6.5% of quarterly revenue.

The case against. Wearables are the largest swing factor.

Read the full bull and bear case on ESLOY, including what would have to change to break either one. Walnut is not an investment adviser.

How is EssilorLuxottica (ESLOY) valued?

Market cap, P/E and dividend yield at today's price are in the ESLOY key stats above. The business figures below come from EssilorLuxottica's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~€29.3B (+5.7% latest quarter, reported)
  • Q3 2026 revenue: ~€7.49B (+7.2% constant currency)
  • Margins (TTM: gross / operating / net): ~60% / ~13% / ~8.5%
  • Net income (TTM): ~€2.5B
  • Dividend: €4.00 per share (~2.4% yield), ~€2.00 per ADR

As of November 2026: Trailing reported earnings understate the business because they include amortisation from the 2018 merger and other acquisitions; adjusted net profit was ~€3.16 billion in 2025 and ~€1.92 billion in the first half of 2026. On forward estimates the ADR trades near ~22x, down from well above 40x at the late 2025 peak and roughly in line with large European consumer health names. EV/EBITDA is ~18x on Yahoo's figures, and the price is ~3x sales. The two analysts Yahoo tracks on the ADR have a mean target of ~$132.50, well above the ~$96 close. Net debt of ~€13.4 billion is about 2x EBITDA. Each ESLOY ADR equals 0.5 ordinary shares, so the ADR price is roughly half the Paris price converted into dollars at ~$1.11 per euro.

Who competes with EssilorLuxottica (ESLOY)?

Lens makers and eye-care medtech

Hoya (Japan) and privately held Carl Zeiss are the main rivals in prescription lenses, and Hoya's MiYOSMART competes directly with Stellest in children's myopia control. CooperVision's MiSight contact lens and Alcon compete in myopia and broader eye care. These companies matter most to the highest-margin part of EssilorLuxottica's business.

Frames, sunglasses and optical retail

Safilo, Marcolin, Kering Eyewear and LVMH's Thélios make branded and licensed frames, and Kering and LVMH have pulled licences in-house over the past decade. In retail, Warby Parker, National Vision, Specsavers, Fielmann and Costco compete with LensCrafters and Sunglass Hut on price and convenience, especially in the US.

Smart glasses and big tech

Google is launching Gemini-powered glasses with Warby Parker and Gentle Monster, Apple is reported to be working on glasses for 2027, and Snap, Xiaomi and Amazon have their own products. These rivals threaten Ray-Ban Meta's early lead and could push AI glasses toward commodity hardware, which would hurt EssilorLuxottica's pricing power.

What stocks are similar to EssilorLuxottica (ESLOY)?

Other names that sit close to ESLOY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in EssilorLuxottica (ESLOY)

There are three common ways to get ESLOY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ESLOY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ESLOY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on EssilorLuxottica (ESLOY)

EssilorLuxottica pairs a dominant, slow-moving lens and frame business with a fast but volatile AI glasses line, so ESLOY moves on whether wearables growth and margins hold up against Google and Apple.

More on EssilorLuxottica (ESLOY)

Whether ESLOY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ESLOY a buy or a sell?, and where the stock could go from here in the ESLOY stock forecast.

For income investors, whether ESLOY pays a dividend and how the payout looks is covered in does ESLOY pay a dividend? And to weigh ESLOY against a peer, read the full side-by-side comparisons: ESLOY vs ALC and ESLOY vs LVMUY.

Wondering how ESLOY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about EssilorLuxottica

Ask Walnut's AI anything about ESLOY and see how it fits what you own.

FAQ

What is ESLOY?

+

ESLOY is the ticker for EssilorLuxottica's sponsored American Depositary Receipt, which trades over the counter in the US. EssilorLuxottica's main listing is on Euronext Paris under the symbol EL, and it is part of the CAC 40 and Euro Stoxx 50. The ADR lets US investors hold the company through an ordinary US brokerage account in dollars, without buying shares in euros on a foreign exchange. One ESLOY ADR represents half of one ordinary share, so two ADRs equal one Paris share. On November 20, 2026 the ADR closed at ~$95.79. ESLOY is quoted on the OTC market, not on the NYSE or Nasdaq, so trading volume is lower and bid/ask spreads can be wider than on the Paris listing.

How do I invest in EssilorLuxottica from the US?

+

The simplest route is to buy ESLOY through a US brokerage that supports OTC securities. Most large brokers such as Fidelity, Schwab and Interactive Brokers allow it, though some apps restrict or do not offer certain OTC ADRs, and a few may add a fee. A second route is buying the Paris-listed EL shares directly through a broker with international access, which gives deeper liquidity but means trading in euros. A third route is a fund that holds the stock, such as a Europe or Euro Stoxx 50 ETF, where EssilorLuxottica is one holding among many. Each route carries currency exposure, since the company earns and reports in euros even when the ADR is priced in dollars. Walnut can show where an ESLOY position sits in a connected portfolio but does not tell anyone whether to buy it.

What does EssilorLuxottica actually sell?

+

It sells nearly everything involved in buying glasses. On the lens side it makes Varilux progressive lenses, Crizal coatings, Transitions light-adaptive lenses and Stellest lenses for children's myopia. On the frame side it owns Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear and others, and it makes licensed eyewear for luxury houses including Chanel, Prada and Miu Miu. It runs retail chains such as LensCrafters, Sunglass Hut, Target Optical, Pearle Vision franchises and Salmoiraghi & Viganò, plus an online business and EyeMed vision insurance in the US. Newer lines include Ray-Ban Meta and Oakley Meta AI glasses, Nuance Audio hearing glasses and medical devices such as Heidelberg Engineering's diagnostic imaging. Revenue is split between Professional Solutions (selling to opticians) and Direct-to-Consumer (its own stores and websites).

How did EssilorLuxottica do in the third quarter of 2026?

+

Third-quarter revenue, reported on October 20, 2026, was ~€7.49 billion, up 9% at current exchange rates and 7.2% at constant currency, ahead of the ~€7.36 billion analysts had expected. Direct-to-consumer sales grew 10.6% to ~€4.09 billion and Professional Solutions grew 3.4% to ~€3.39 billion. By region, Asia-Pacific grew 15.7%, EMEA 7.5%, Latin America 7.1% and North America 4.7%. Wearables brought in ~€486 million, up 20%, and myopia management grew 24%. Over nine months revenue reached ~€22.3 billion, up 8.9% at constant currency. The Paris shares rose about 14% the next day, as stronger traditional eyewear sales eased concerns about slowing AI glasses growth. The company reports only revenue in the third quarter; profit figures come with the full-year results in February.

Why did EssilorLuxottica stock fall so much from its 2025 high?

+

The Paris shares peaked above €320 in late 2025, when Ray-Ban Meta sales were doubling and investors priced the company partly as an AI hardware play. Through 2026 several things cut that premium. Google showed Gemini-powered glasses with Warby Parker and Gentle Monster, Bloomberg reported Apple was accelerating its own glasses, and Goldman Sachs downgraded the stock to Neutral in July 2026 on expectations of slower AI glasses growth. Meta paused Ray-Ban Display launches outside the US because of supply shortages. Margins fell in 2025 as the company invested heavily, and US tariffs and a weaker dollar weighed on reported results. The shares hit a low near €138 before recovering to about €180 after the third-quarter beat. The ADR followed the same path, from about $182 at its 52-week high to a low near $79, and it has given back much of the October bounce, closing at ~$95.79 on November 20, 2026.

How important are Ray-Ban Meta glasses to the company?

+

Wearables, which include Meta AI glasses and Nuance Audio, produced ~€1.26 billion over the first nine months of 2026, roughly 5.6% of group revenue. Growth has been fast, nearly doubling in the second quarter of 2026, then slowing to 20% in the third. The partnership runs into the 2030s, and Meta has bought roughly a 3% stake in EssilorLuxottica. Meta supplies the AI, software and chips while EssilorLuxottica designs, makes and sells the frames under its brands. Because the stock rose and fell with AI glasses headlines through 2025 and 2026, quarterly wearables numbers and news from Google, Apple or Meta often move ESLOY more than the much larger lens and frame business does.

Does ESLOY pay a dividend?

+

Yes. EssilorLuxottica paid a €4.00 dividend per ordinary share for 2025, once a year in June, which works out to roughly €2.00 per ESLOY ADR before fees and taxes, or about $2.20 at ~$1.11 per euro. At the November 20, 2026 ADR price that is a yield of roughly 2.4%. The company offers a scrip option, letting holders take new shares instead of cash, and about 70% of shareholders chose shares in 2026. ADR holders usually receive cash converted into dollars by the depositary bank. France withholds tax on dividends paid to foreign holders, typically 25% at source, and US investors may be able to reclaim part of that under the US-France tax treaty and claim a foreign tax credit. The dollar amount received changes with the exchange rate on the payment date.

What are the main risks of holding ESLOY?

+

The largest is competition in AI glasses from Google, Apple and others, which could slow wearables growth and cut the price the market assigns to that line. The company also depends on Meta for the AI and software, so a change in Meta's strategy would matter. US tariffs on frames made in Italy and China can squeeze margins, and North America is about 43% of revenue. For a US holder, a weaker dollar lowers reported euro revenue from the US, while the euro/dollar rate also moves the ADR price directly. The shares trade at ~22x forward earnings, so a miss can produce sharp moves like the swings seen in 2026. Net debt of ~€13.4 billion, gradual dilution from the scrip dividend and thinner OTC trading in ESLOY are smaller but real considerations.

How has ESLOY stock performed in 2026?

+

As of November 20, 2026, ESLOY closed at ~$95.79, down 38.6% year to date and 46% over one year, and 5.7% lower over the past month. The ADR's 52-week range runs from ~$79 to ~$182. Most of the fall came in the first half of 2026 as investors worried about Google and Apple entering AI glasses, slower Ray-Ban Meta growth and thinner margins. The third-quarter revenue beat on October 20 lifted the shares about 14% in a day, but that gain has largely faded. At the current price the ADR trades at ~31x trailing and ~22x forward earnings, with a dividend yield of roughly 2.4%. Full-year 2026 results, including profit, are due in February.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with EssilorLuxottica's investor relations page or your broker before making investment decisions.